Brokerages Anticipate Ultragenyx Pharmaceutical Inc (RARE) Will Announce Earnings of -$1.74 Per Share

Wall Street analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post earnings per share of ($1.74) for the current quarter, according to Zacks. Seven analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.57) and the lowest estimate coming in at ($1.86). Ultragenyx Pharmaceutical posted earnings of $0.62 per share in the same quarter last year, which suggests a negative year over year growth rate of 380.6%. The firm is expected to announce its next earnings report on Monday, May 6th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.79) per share for the current financial year, with EPS estimates ranging from ($7.48) to ($6.00). For the next financial year, analysts expect that the company will post earnings of ($4.99) per share, with EPS estimates ranging from ($5.73) to ($3.77). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. The business had revenue of $16.26 million for the quarter, compared to analyst estimates of $13.30 million.

A number of equities analysts recently issued reports on RARE shares. Zacks Investment Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, December 31st. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, November 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 14th. Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 7th. Finally, SunTrust Banks boosted their target price on shares of Ultragenyx Pharmaceutical to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 23rd. Seven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $76.16.

Institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 5.4% in the 3rd quarter. Alliancebernstein L.P. now owns 992,357 shares of the biopharmaceutical company’s stock worth $75,757,000 after purchasing an additional 50,489 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Ultragenyx Pharmaceutical by 5.3% in the 3rd quarter. Wells Fargo & Company MN now owns 23,742 shares of the biopharmaceutical company’s stock worth $1,812,000 after purchasing an additional 1,194 shares during the last quarter. Capital Impact Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 31.7% in the 4th quarter. Capital Impact Advisors LLC now owns 37,858 shares of the biopharmaceutical company’s stock worth $1,585,000 after purchasing an additional 9,112 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $1,954,000. Finally, Kiwi Wealth Investments Limited Partnership bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $958,000. 99.20% of the stock is currently owned by hedge funds and other institutional investors.

RARE stock traded down $2.14 on Thursday, reaching $65.80. 408,232 shares of the company were exchanged, compared to its average volume of 662,824. Ultragenyx Pharmaceutical has a 12 month low of $37.44 and a 12 month high of $90.98. The firm has a market capitalization of $3.48 billion, a P/E ratio of -8.90 and a beta of 2.21.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Story: Net Asset Value

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.